F&G Annuities & Life reports Q1 2026 results today, but the most striking setup detail arrived two months ago: CEO Christopher Blunt bought 10,000 shares at $20.99 on March 13, putting roughly $210,000 of personal capital behind the stock near its recent lows.
That signal looks well-timed. The stock closed at $29.47 on Wednesday — up 40% from Blunt's entry — and has gained 13% over the past month alone. The CEO's March purchase followed a February earnings release that crushed the stock, which fell nearly 16% in a single session and extended those losses to around 18% over five days. An independent director added 4,760 shares the same day at similar prices. That cluster of insider buying, with two insiders stepping in at the lows after a sharp post-earnings drop, is a meaningful vote of confidence. The 90-day net insider position is modestly positive at roughly $1.6 million in net value, though it is worth noting that Blunt himself sold 39,588 shares in December at $32.66 before the February rout.
The broader ownership picture reflects a tightly controlled float. Parent company Fidelity National Financial holds 71% of shares, which compresses the effective tradeable base. BlackRock added 2.8 million shares in the most recent reported quarter, and Vanguard added 1.75 million — both passive managers building positions as the stock declined. Institutional demand at the margin has been incremental and constructive.
Short interest is modest rather than threatening. At just over 2% of the free float with borrowing costs running near 0.57% and availability at a comfortable level, there is no short-side pressure to speak of. The ORTEX short score of 50 is essentially neutral, and the RSI has climbed to 71 — technically extended after the recent run. Options positioning is also benign: the put/call ratio of 0.72 sits fractionally below its 20-day average of 0.73, implying no unusual hedging demand into the print. The analyst picture is harder to read — the most recent formal target revision, from Barclays in early April, cut the target to $27, now sitting below the current price of $29.47.
The Q1 print tests whether the annuity franchises's earnings power can justify the recovery from February's post-earnings selloff — and whether management's forward commentary gives the market reason to hold gains above the level where its own CEO was a buyer.
See the live data behind this article on ORTEX.
Open FG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
